Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

about

Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.

P2860

Q38632940-B4755A9D-009B-4990-BA05-5356E8611A37 Q39018189-7A43EE16-9CB7-4557-B9C2-95CF08FE4651

P2860

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q38537523

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

@en

type

Item

label

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

@en

prefLabel

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

@en

P1476

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

@en

P2093

Aleksandra Mamorska-Dyga

http://www.w3.org/2001/XMLSchema#string

Karen Seiter

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development

The biology of CD20 and its potential as a target for mAb therapy

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

P304

951-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/CIA.S69278

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2015-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26109852

http://www.w3.org/2001/XMLSchema#string

P921

chronic lymphocytic leukemia

globulins

monoclonal antibody

blood proteins

P932

4472072

http://www.w3.org/2001/XMLSchema#string

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

about

P2860

P2860

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932